000061661 001__ 61661
000061661 005__ 20191105115759.0
000061661 0247_ $$2doi$$a10.1016/j.redox.2017.05.026
000061661 0248_ $$2sideral$$a99643
000061661 037__ $$aART-2017-99643
000061661 041__ $$aeng
000061661 100__ $$0(orcid)0000-0002-4379-1100$$aLlobet, L.
000061661 245__ $$aPharmacologic concentrations of linezolid modify oxidative phosphorylation function and adipocyte secretome
000061661 260__ $$c2017
000061661 5060_ $$aAccess copy available to the general public$$fUnrestricted
000061661 5203_ $$aThe oxidative phosphorylation system is important for adipocyte differentiation. Therefore, xenobiotics inhibitors of the oxidative phosphorylation system could affect adipocyte differentiation and adipokine secretion. As adipokines impact the overall health status, these xenobiotics may have wide effects on human health. Some of these xenobiotics are widely used therapeutic drugs, such as ribosomal antibiotics. Because of its similarity to the bacterial one, mitochondrial translation system is an off-target for these compounds. To study the influence of the ribosomal antibiotic linezolid on adipokine production, we analyzed its effects on adipocyte secretome. Linezolid, at therapeutic concentrations, modifies the levels of apolipoprotein E and several adipokines and proteins related with the extracellular matrix. This antibiotic also alters the global methylation status of human adipose tissue-derived stem cells and, therefore, its effects are not limited to the exposure period. Besides their consequences on other tissues, xenobiotics acting on the adipocyte oxidative phosphorylation system alter apolipoprotein E and adipokine production, secondarily contributing to their systemic effects.
000061661 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B33$$9info:eu-repo/grantAgreement/ES/FIS/PI14-00005$$9info:eu-repo/grantAgreement/ES/FIS/PI14-00070
000061661 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000061661 590__ $$a7.126$$b2017
000061661 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b31 / 292 = 0.106$$c2017$$dQ1$$eT1
000061661 592__ $$a2.203$$b2017
000061661 593__ $$aBiochemistry$$c2017$$dQ1
000061661 593__ $$aOrganic Chemistry$$c2017$$dQ1
000061661 593__ $$aClinical Biochemistry$$c2017$$dQ1
000061661 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000061661 700__ $$0(orcid)0000-0002-8585-6371$$aBayona-Bafaluy, M.P.$$uUniversidad de Zaragoza
000061661 700__ $$aPacheu-Grau, D.
000061661 700__ $$aTorres-Pérez, E.
000061661 700__ $$aArbones-Mainar, J.M.
000061661 700__ $$0(orcid)0000-0002-0108-1004$$aNavarro, M.Á.$$uUniversidad de Zaragoza
000061661 700__ $$aGómez-Díaz, C.
000061661 700__ $$0(orcid)0000-0003-1770-6299$$aMontoya, J.$$uUniversidad de Zaragoza
000061661 700__ $$0(orcid)0000-0002-3217-1424$$aLópez-Gallardo, E.$$uUniversidad de Zaragoza
000061661 700__ $$0(orcid)0000-0002-0269-7337$$aRuiz-Pesini, E.$$uUniversidad de Zaragoza
000061661 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000061661 773__ $$g13 (2017), 244-254$$pRedox biol.$$tRedox Biology$$x2213-2317
000061661 8564_ $$s1033065$$uhttps://zaguan.unizar.es/record/61661/files/texto_completo.pdf$$yVersión publicada
000061661 8564_ $$s98013$$uhttps://zaguan.unizar.es/record/61661/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000061661 909CO $$ooai:zaguan.unizar.es:61661$$particulos$$pdriver
000061661 951__ $$a2019-11-05-11:49:54
000061661 980__ $$aARTICLE